{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:57:14Z","timestamp":1792580234462,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":194,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000035","name":"CIHR INMD","doi-asserted-by":"publisher","award":["PJ8-169695"],"award-info":[{"award-number":["PJ8-169695"]}],"id":[{"id":"10.13039\/501100000035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.prdoa.2022.100155","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T11:08:36Z","timestamp":1657969716000},"page":"100155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Imaging pathological tau in atypical parkinsonisms: A review"],"prefix":"10.1016","volume":"7","author":[{"given":"Anastassia M.","family":"Mena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio P.","family":"Strafella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatric Med."},{"issue":"3","key":"10.1016\/j.prdoa.2022.100155_b0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/ijms18030551","article-title":"Parkinson\u2019s Disease: From Pathogenesis to Pharmacogenomics","volume":"18","author":"Cacabelos","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.23713","article-title":"Milestones in atypical and secondary Parkinsonisms","volume":"26","author":"Wenning","year":"2011","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.prdoa.2022.100155_b0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1212\/CON.0000000000000751","article-title":"Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy","volume":"25","author":"Greene","year":"2019","journal-title":"Continuum Lifelong Learn. Neurol."},{"issue":"4","key":"10.1016\/j.prdoa.2022.100155_b0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia","volume":"10","author":"Steele","year":"1964","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.prdoa.2022.100155_b0030","doi-asserted-by":"crossref","first-page":"101644","DOI":"10.1016\/j.pneurobio.2019.101644","article-title":"Four-repeat tauopathies","volume":"180","author":"R\u00f6sler","year":"2019","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JPD-202302","article-title":"Genetics of progressive supranuclear palsy: A review","volume":"11","author":"Wen","year":"2021","journal-title":"J. Parkinson\u2019s Disease"},{"key":"10.1016\/j.prdoa.2022.100155_b0040","first-page":"139","article-title":"Progressive Supranuclear Palsy: Advances in Diagnosis and Management","volume":"176","author":"Coughlin","year":"2017","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.prdoa.2022.100155_b0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.irn.2019.10.013","article-title":"Progressive supranuclear palsy","volume":"149","author":"Giagkou","year":"2019","journal-title":"Int. Rev. Neurobiol."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0050","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1212\/WNL.0000000000009734","article-title":"Clinical and pathologic features of cognitive-predominant corticobasal degeneration","volume":"95","author":"Sakae","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2022.100155_b0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2019.07.030","article-title":"Dystonia in atypical parkinsonian disorders","volume":"66","author":"Marsili","year":"2019","journal-title":"Parkinsonism Rel. Disorders"},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14802\/jmd.17071","article-title":"Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms","volume":"11","author":"Hyoung Lyoo","year":"2018","journal-title":"J. Movement Disorders"},{"issue":"2","key":"10.1016\/j.prdoa.2022.100155_b0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1152\/physrev.00024.2003","article-title":"Role of tau protein in both physiological and pathological conditions","volume":"84","author":"Avila","year":"2004","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.prdoa.2022.100155_b0075","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2990.2003.00463.x","article-title":"Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies","volume":"29","author":"De Silva","year":"2003","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.prdoa.2022.100155_b0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2022.100155_b0085","unstructured":"G.G. Kovacs, Chapter 25 Tauopathies, Handbook Clin. Neurol. 145(3) (2018)."},{"issue":"11","key":"10.1016\/j.prdoa.2022.100155_b0090","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","article-title":"Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration","volume":"61","author":"Dickson","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0095","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/brain\/awm104","article-title":"Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome","volume":"130","author":"Williams","year":"2007","journal-title":"Brain"},{"issue":"7880","key":"10.1016\/j.prdoa.2022.100155_b0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","article-title":"Structure-based classification of tauopathies","volume":"598","author":"Shi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.prdoa.2022.100155_b0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.04.014","article-title":"Progressive Supranuclear Palsy and Corticobasal Degeneration","volume":"73","author":"Coughlin","year":"2020","journal-title":"Clin. Parkinsonism Rel. Disorders"},{"issue":"5","key":"10.1016\/j.prdoa.2022.100155_b0110","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/brain\/112.5.1171","article-title":"Corticobasal degeneration","volume":"112","author":"Gibb","year":"1989","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.prdoa.2022.100155_b0115","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/neup.12590","article-title":"Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration","volume":"40","author":"Mimuro","year":"2020","journal-title":"Neuropathology"},{"issue":"5","key":"10.1016\/j.prdoa.2022.100155_b0125","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/ane.12067","article-title":"Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools","volume":"127","author":"Liscic","year":"2013","journal-title":"Acta Neurol."},{"issue":"18","key":"10.1016\/j.prdoa.2022.100155_b0130","first-page":"1818","article-title":"Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging","volume":"23","author":"Pike","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"8","key":"10.1016\/j.prdoa.2022.100155_b0135","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies \u2013 still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.prdoa.2022.100155_b0140","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimer\u2019s Dementia J."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0145","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/ana.25911","article-title":"Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy","volume":"88","author":"Malpetti","year":"2020","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.prdoa.2022.100155_b0150","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ana.25893","article-title":"Sensitivity-Specificity of Tau and Amyloid \u03b2 Positron Emission Tomography in Frontotemporal Lobar Degeneration","volume":"88","author":"Ghirelli","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.prdoa.2022.100155_b0155","article-title":"Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants","volume":"25","author":"Whitwell","year":"2019","journal-title":"NeuroImage: Clinical"},{"issue":"2","key":"10.1016\/j.prdoa.2022.100155_b0160","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00415-019-09566-9","article-title":"18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy","volume":"267","author":"Nicastro","year":"2020","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0165","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/brain\/awaa383","article-title":"F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome","volume":"144","author":"Goodheart","year":"2021","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.prdoa.2022.100155_b0170","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.0000000000004364","article-title":"18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome","volume":"89","author":"Cho","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.prdoa.2022.100155_b0175","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.25060","article-title":"18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study","volume":"82","author":"Schonhaut","year":"2017","journal-title":"Ann. Neurol."},{"issue":"13","key":"10.1016\/j.prdoa.2022.100155_b0180","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00259-018-4104-2","article-title":"Disease-related patterns of in vivo pathology in Corticobasal syndrome","volume":"45","author":"Niccolini","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.prdoa.2022.100155_b0185","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00401-016-1618-1","article-title":"[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration","volume":"132","author":"Josephs","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.prdoa.2022.100155_b0190","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1640-3","article-title":"Multimodal evaluation demonstrates in vivo 18 F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration","volume":"132","author":"Mcmillan","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.27546","article-title":"MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy","volume":"34","author":"Whitwell","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2022.100155_b0200","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1093\/brain\/awaa276","article-title":"F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"143","author":"Soleimani-Meigooni","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.prdoa.2022.100155_b0205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","article-title":"F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes","volume":"11","author":"Tsai","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0210","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.26844","article-title":"Subcortical 18F-AV-1451 binding patterns in progressive supranuclear palsy","volume":"32","author":"Cho","year":"2017","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.prdoa.2022.100155_b0215","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1177\/0271678X16683695","article-title":"Positron emission tomography imaging of tau pathology in progressive supranuclear palsy","volume":"37","author":"Coakeley","year":"2017","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.prdoa.2022.100155_b0220","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00429-017-1507-y","article-title":"[18 F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP","volume":"223","author":"Coakeley","year":"2017","journal-title":"Brain Struct. Funct."},{"issue":"8","key":"10.1016\/j.prdoa.2022.100155_b0225","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/mds.27356","article-title":"[18 F]AV-1451 binding and postmortem pathology of CBD","volume":"33","author":"Coakeley","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2022.100155_b0230","article-title":"Molecular pathology and synaptic loss in primary tauopathies: an 18 F-AV-1451 and 11 C-UCB-J PET study","author":"Holland","year":"2021","journal-title":"Brain"},{"issue":"13","key":"10.1016\/j.prdoa.2022.100155_b0235","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/acschemneuro.0c00340","article-title":"Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer\u2019s Tauopathy","volume":"12","author":"Murugan","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.prdoa.2022.100155_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2018.00174","article-title":"Comparison of 18F\u2013T807 and 18F-THK5117 PET in a mouse model of tau pathology","volume":"10","author":"Brendel","year":"2018","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.24844","article-title":"Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies","volume":"81","author":"Marqui\u00e9","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.prdoa.2022.100155_b0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00401-016-1650-1","article-title":"Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy","volume":"133","author":"Smith","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0255","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mds.26727","article-title":"Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy","volume":"32","author":"Hammes","year":"2017","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0260","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00259-019-04305-8","article-title":"Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging","volume":"46","author":"Murugan","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0265","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-130032","article-title":"PET imaging of neuropathology in tauopathies: Progressive supranuclear palsy","volume":"36","author":"Kepe","year":"2013","journal-title":"J. Alzheimer\u2019s Disease"},{"key":"10.1016\/j.prdoa.2022.100155_b0270","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3233\/JAD-160698","article-title":"Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-beta and Tau in Parkinson\u2019s Disease","volume":"55","author":"Buongiorno","year":"2017","journal-title":"J. Alzheimer\u2019s Disease"},{"key":"10.1016\/j.prdoa.2022.100155_b0275","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","article-title":"Imaging in-vivo tau pathology in Alzheimer\u2019s disease with THK5317 PET in a multimodal paradigm","volume":"43","author":"Chiotis","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.prdoa.2022.100155_b0280","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/mp.2017.108","article-title":"Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer\u2019s disease dementia","volume":"23","author":"Chiotis","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.prdoa.2022.100155_b0285","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","article-title":"The development and validation of tau PET tracers: current status and future directions","volume":"6","author":"Okamura","year":"2018","journal-title":"Clin. Transl. Imaging"},{"issue":"4","key":"10.1016\/j.prdoa.2022.100155_b0290","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2967\/jnumed.117.197426","article-title":"Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease","volume":"59","author":"Harada","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0295","doi-asserted-by":"crossref","first-page":"996","DOI":"10.2967\/jnumed.116.182980","article-title":"In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317","volume":"58","author":"Betthauser","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0300","article-title":"Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy","volume":"6","author":"Ishiki","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0305","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ene.13164","article-title":"Tau imaging with [(18) F]THK-5351 in progressive supranuclear palsy","volume":"24","author":"Ishiki","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2022.100155_b0310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fnagi.2017.00440","article-title":"[(18)F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy","volume":"9","author":"Brendel","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syn- drome): Report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2022.100155_b0320","first-page":"1","article-title":"Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain","volume":"9","author":"Ng","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0325","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Article imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.prdoa.2022.100155_b0330","doi-asserted-by":"crossref","first-page":"9034","DOI":"10.1073\/pnas.1530287100","article-title":"Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure","volume":"100","author":"Berriman","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.prdoa.2022.100155_b0335","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/RLU.0000000000002949","article-title":"Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome: A 11C-Pyridinyl-Butadienyl-Benzothiazole 3 PET Pilot Study","volume":"45","author":"Schr\u00f6ter","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.prdoa.2022.100155_b0340","doi-asserted-by":"crossref","DOI":"10.1007\/BF03161076","article-title":"Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration","volume":"246","author":"Dickson","year":"1999","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.prdoa.2022.100155_b0345","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jlcr.3890","article-title":"Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [18F]PM-PBB3 for clinical applications","volume":"64","author":"Kawamura","year":"2021","journal-title":"J. Label Compd. Radiopharm."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0350","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JAD-200287","article-title":"Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation","volume":"76","author":"Su","year":"2020","journal-title":"J. Alzheimer\u2019s Disease"},{"key":"10.1016\/j.prdoa.2022.100155_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2020.00604","article-title":"Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer\u2019s Disease Patients With Cognition and Glucose Metabolism","volume":"14","author":"Lu","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.prdoa.2022.100155_b0360","first-page":"1","article-title":"In Vivo 18 F-APN-1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross-Sectional and Longitudinal Findings","author":"Zhou","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2022.100155_b0365","doi-asserted-by":"crossref","first-page":"117440","DOI":"10.1016\/j.jns.2021.117440","article-title":"A case of progressive supranuclear palsy with predominant cerebellar ataxia diagnosed by [18 F] PM-PBB3 tau PET","volume":"425","author":"Ishizuchi","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.prdoa.2022.100155_b0370","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.28672","article-title":"Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). Clinical Utility of 18 F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy","volume":"36","author":"Li","year":"2021","journal-title":"Movement Disorders"},{"issue":"8","key":"10.1016\/j.prdoa.2022.100155_b0375","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1007\/s10072-021-05287-y","article-title":"A case of tauopathy with auditory agnosia and dysprosody diagnosed by [18F]PM-PBB3 tau PET scan","volume":"42","author":"Mashima","year":"2021","journal-title":"Neurol. Sci."},{"issue":"10","key":"10.1016\/j.prdoa.2022.100155_b0380","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","article-title":"Discovery and preclinical characterization of [18 F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies","volume":"46","author":"Kroth","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.prdoa.2022.100155_b0385","doi-asserted-by":"crossref","first-page":"12808","DOI":"10.1021\/acs.jmedchem.1c00861","article-title":"PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer\u2019s Disease and Other Tauopathies","volume":"64","author":"Kroth","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0390","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2967\/jnumed.119.236224","article-title":"Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: A first-in-humans study","volume":"61","author":"Mueller","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100155_b0395","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2967\/jnumed.119.236240","article-title":"Evaluation of dosimetry, quantitative methods, and test-Retest variability of 18F-PI-2620 PET for the assessment of tau deposits in the human brain","volume":"61","author":"Bullich","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.prdoa.2022.100155_b0400","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab190","article-title":"Evaluation of [18 F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies","volume":"3","author":"Tezuka","year":"2021","journal-title":"Brain Commun."},{"issue":"11","key":"10.1016\/j.prdoa.2022.100155_b0405","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/RLU.0000000000003261","article-title":"Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared with 18F-THK-5351","volume":"45","author":"Oh","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.prdoa.2022.100155_b0410","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/mds.28624","article-title":"Cortical [18F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes","volume":"36","author":"Palleis","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2022.100155_b0415","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","article-title":"Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy","volume":"77","author":"Brendel","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.prdoa.2022.100155_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/6640054","article-title":"The Evaluation of Tau Deposition with [18F]PI-2620 by Using a Semiquantitative Method in Cognitively Normal Subjects and Patients with Mild Cognitive Impairment and Alzheimer\u2019s Disease","volume":"2021","author":"Jantarato","year":"2021","journal-title":"Mol. Imaging"},{"issue":"12","key":"10.1016\/j.prdoa.2022.100155_b0425","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1007\/s00259-021-05391-3","article-title":"Feasibility of short imaging protocols for [18 F]PI-2620 tau-PET in progressive supranuclear palsy","volume":"48","author":"Song","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.prdoa.2022.100155_b0430","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2967\/jnumed.117.196741","article-title":"Preclinical evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease","volume":"59","author":"Honer","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.prdoa.2022.100155_b0435","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.118.209916","article-title":"Characterization of 3 novel tau radiopharmaceuticals,11C-RO-963,11C-RO-643, and18F-RO-948, in healthy controls and in Alzheimer subjects","volume":"59","author":"Wong","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.prdoa.2022.100155_b0440","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-019-04496-0","article-title":"Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948","volume":"47","author":"Smith","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.prdoa.2022.100155_b0445","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","article-title":"Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of alzheimer disease from other neurodegenerative disorders","volume":"77","author":"Leuzy","year":"2020","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.prdoa.2022.100155_b0450","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.prdoa.2022.100155_b0455","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1177\/0271678X211031035","article-title":"Evaluation of [18F]-JNJ-64326067-AAA tau PET tracer in humans","volume":"41","author":"Baker","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"10","key":"10.1016\/j.prdoa.2022.100155_b0460","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","article-title":"Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles","volume":"57","author":"Hostetler","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.prdoa.2022.100155_b0465","first-page":"1","article-title":"In vivo quantification of neurofibrillary tangles with [18 F]MK-6240","volume":"10","author":"Pascoal","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"11","key":"10.1016\/j.prdoa.2022.100155_b0470","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1177\/0271678X19887781","article-title":"Test\u2013retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer\u2019s disease","volume":"40","author":"Salinas","year":"2020","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.prdoa.2022.100155_b0475","article-title":"Direct comparison of the tau PET tracers [18 F]flortaucipir and [18 F]MK-6240 in human subjects","author":"Gogola","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.prdoa.2022.100155_b0480","first-page":"1","article-title":"18F-MK-6240 tau-PET in genetic frontotemporal dementia","author":"Levy","year":"2021","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.prdoa.2022.100155_b0485","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/acschemneuro.0c00801","article-title":"Radiosynthesis, in Vitro and in Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies","volume":"12","author":"Lindberg","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"17","key":"10.1016\/j.prdoa.2022.100155_b0490","article-title":"Current radiotracers to image neurodegenerative diseases","volume":"4","author":"Tiepolt","year":"2019","journal-title":"EJNMMI Radiopharmacy Chem."},{"issue":"7","key":"10.1016\/j.prdoa.2022.100155_b0495","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3390\/molecules25071750","article-title":"Characterization of 18F-PM-PBB3 (18F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy","volume":"25","author":"Weng","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.prdoa.2022.100155_b0500","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-021-00790-x","article-title":"A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240","volume":"11","author":"Kolinger","year":"2021","journal-title":"EJNMMI Res."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112522000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112522000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:46:36Z","timestamp":1762911996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112522000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":100,"alternative-id":["S2590112522000263"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2022.100155","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging pathological tau in atypical parkinsonisms: A review","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2022.100155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100155"}}